USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients
USV Pvt. Ltd, a leading drug manufacturer in the diabetes & cardiology segment, has announced the launch of the Liralin Range for the treatment of type 2 diabetes in Indian patients.
USV's Liralin Range is launched in 3 SKU forms: Liralin, Liralin DP & Liralin M. Liralin M will be introduced soon.
Liralin contains Linagliptin 5 mg, whereas Liralin DP is an FDC of Linagliptin 5 mg & Dapagliflozin 10 mg. Liralin M is an FDC containing Linagliptin 5 mg & Metformin 1000 mg
Liralin DP is available at INR 19.9/- per tablet, while Liralin is priced at INR 11.9/- per tablet.
Linagliptin has multiple clinical and safety advantages, making it potentially an evergreen OAD agent as monotherapy and in combination with other agents.
Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by USV Private Limited.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.